Denver, May 16, 2014 (GLOBE NEWSWIRE) -- FusionPharm, Inc. (FSPM) (the "Company"), the Denver
based manufacturer of the PharmPods™ cultivation system, (www.pharmpods.com) is pleased to
announce that the Company generated revenue of $305,000 for the
quarter ending March 31, 2014, which represents the Company's
delivery of 10 PharmPods. During the quarter, the Company
manufactured 24 PharmPods for customer orders, representing its
largest quarter to date in manufacturing. The Company had a
net loss of $47,795 for the quarter, primarily attributable to the
start up nature of its business and the scaling of the Company's
operations. The Company is actively working to streamline its
purchasing and manufacturing processes to improve margins. At
the end of the quarter, the Company had $482,000 in signed
contracts providing for construction of 20 PharmPod containers,
$314,000 of which has been received in deposits. As of
quarter end, the Company had $674,000 in the bank to fund ongoing
operations.
Update from CEO Scott Dittman
I recently spent a week up in Canada where I helped a key client
of ours with the installation of the first phase (6 PharmPods) of a
48 pod overall phased installation plan. While we don't have
firm orders for the remaining 42 PharmPods, our customer's 15,000
thousand square foot facility was custom built to house PharmPods,
which typifies our sales cycle and how we see the market evolving.
We're seeing clients (and prospective clients) designing
large-scale facilities to specifically house PharmPods and then
making their firm purchases on a staggered basis with overall build
out timeframes often in excess of one year. This is one of
the many benefits to our customers of using PharmPods, they can
build very large commercial cultivation centers with phased
installation as the product demand and plant inventory grows.
As our clients cultivation needs increase, we simply deliver them
more pods to plug in and add production capacity.
This is a huge advantage over traditional cultivation facilities
that must be completely built out at the outset, significantly
speeding time to market for PharmPod cultivators.
Year to Date Highlights:
· Raised
$1,010,000 in additional equity from the sale of 681,667 shares of
restricted common stock.
· Retired all of
our outstanding debt.
· More than
doubled the size of our manufacturing facility
· Received ETL
(Edison Testing Laboratories) certification of our PharmPods in the
USA and Canada
· Hired a
product development engineer, office administrator and marketing
specialist, Finance & Administration consultant and a sales
consultant.
· Revised our
product website www.PharmPods.com
· CEO Scott
Dittman participated in various National Cannabis Industry
Association events (FusionPharm is a Founding Member of this
organization) in Massachusetts, Illinois, Oregon, Washington,
Colorado, Nevada and Washington DC.
· CEO Scott
Dittman spent 2 days on Capitol Hill with more than 40 other NCIA
representatives lobbying to enact banking laws and modify IRS rule
280e.
· Completed a
comprehensive update of our marketing material and strategy
· CEO Scott
Dittman was interviewed by iCannabis Radio in January.
· Signed a lease
to open a new sales center in Seattle, opening date to be
announced.
· Had a booth at
the Maximum Yield "Coast to Coast Grow Like A Pro" indoor gardening
expo during April.
About FusionPharm Inc.
(FSPM)
FusionPharm, Inc. (FSPM) (www.fusionpharminc.com)
was organized to capitalize on opportunities present in the rapidly
growing vertical farming and cannabis industries. FusionPharm's
primary focus is the development and deployment of the patent
pending PharmPods™ advanced hydroponic commercial cultivation
systems. PharmPods are constructed from standard ISO steel shipping
containers that are repurposed for use in indoor controlled
environment agriculture. Modular, stackable, cost competitive and
financeable, PharmPods have become the industry leader for
professional, commercial scale indoor plant cultivation.
Cautionary Language Concerning
Forward-Looking Statements
This release contains "forward-looking statements" that include
information relating to future events and future financial and
operating performance. The words "may," "would," "will,"
"expect," "estimate," "can," "believe," "potential" and similar
expressions and variations thereof are intended to identify
forward-looking statements. Forward-looking statements should not
be read as a guarantee of future performance or results.
Forward-looking statements are based on information
available at the time they are made and/or management's good faith
belief as of that time with respect to future events, and are
subject to risks and uncertainties that could cause actual
performance or results to differ materially from those expressed in
or suggested by the forward-looking statements. No information in
this press release should be construed as an indication of the
Company's future financial performance, revenues or stock
price. The Company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
CONTACT: investors@fusionpharminc.com